Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
GAITHERSBURG, Md., April 19, 2018 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2018, recent business developments, revenue guidance for the second quarter of 2018, and revenue and net income guidance for full year 2018.
This conference call can be accessed live by telephone or by webcast:
Live Teleconference Information:
Dial in number: (855) 766-6521
International dial in: (262) 912-6157
Conference ID: 93329114
Live Webcast Information:
Visit https://edge.media-server.com/m6/p/gyy8ca3t for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]
